Compare MLAB & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLAB | SGP |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.9M | 799.4M |
| IPO Year | 1995 | 2026 |
| Metric | MLAB | SGP |
|---|---|---|
| Price | $127.56 | $23.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $117.50 | $44.00 |
| AVG Volume (30 Days) | 89.9K | ★ 122.6K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | ★ 436.11 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $6.45 | N/A |
| P/E Ratio | $261.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.43 | $17.06 |
| 52 Week High | $144.35 | $32.44 |
| Indicator | MLAB | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 40.58 |
| Support Level | $89.77 | $20.95 |
| Resistance Level | $132.70 | $25.83 |
| Average True Range (ATR) | 5.03 | 1.38 |
| MACD | -1.26 | -0.28 |
| Stochastic Oscillator | 15.89 | 24.21 |
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.